{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:28:00Z","timestamp":1793863680943,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jtauto.2026.100388","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:10:47Z","timestamp":1784247047000},"page":"100388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anti-C2\u2013mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravis"],"prefix":"10.1016","volume":"13","author":[{"given":"Britt","family":"Arets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bracke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"De Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Delaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Driege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Delahaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahan","family":"Moshir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Van de Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ulrichts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Man\u00e9-Damas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Losen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Martinez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtauto.2026.100388_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010148","article-title":"Complement as a therapeutic target in systemic autoimmune diseases","volume":"10","author":"Galindo-Izquierdo","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jtauto.2026.100388_bib2","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1038\/s41467-025-62925-1","article-title":"Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart","volume":"16","author":"Van de Walle","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jtauto.2026.100388_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jtauto.2026.100388_bib4","article-title":"Development of an anti-rat complement C2 antibody that improves renal outcome in a rat kidney transplant model","volume":"16","author":"Bracke","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2026.100388_bib5","article-title":"Empasiprubart (Argx-117) in multifocal motor neuropathy: initial safety and efficacy data of the phase 2 arda study","volume":"70","author":"Querol","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jtauto.2026.100388_bib6","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jtauto.2026.100388_bib7","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jtauto.2026.100388_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.pediatrneurol.2024.04.020","article-title":"Eculizumab in adolescent patients with refractory generalized myasthenia gravis: a phase 3, open-label, multicenter study","volume":"156","author":"Brandsema","year":"2024","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.jtauto.2026.100388_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jtauto.2026.100388_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2017.06.007","article-title":"Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab","volume":"183","author":"Puissant-Lubrano","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jtauto.2026.100388_bib11","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.jtauto.2026.100388_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","article-title":"Complement C2 siRNA mediated therapy of myasthenia gravis in mice","volume":"42","author":"Huda","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jtauto.2026.100388_bib13","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3389\/fimmu.2019.02238","article-title":"Absence of the lectin activation pathway of complement ameliorates proteinuria-induced renal injury","volume":"10","author":"Alghadban","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2026.100388_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2017-000652","article-title":"Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction","volume":"5","author":"Clark","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.jtauto.2026.100388_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40478-016-0291-x","article-title":"C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy","volume":"4","author":"McGonigal","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jtauto.2026.100388_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.106009","article-title":"Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function","volume":"122","author":"Ho","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jtauto.2026.100388_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.expneurol.2015.02.025","article-title":"Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs","volume":"270","author":"Kusner","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jtauto.2026.100388_bib18","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/brain\/awh612","article-title":"Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis","volume":"128","author":"Losen","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.jtauto.2026.100388_bib19","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2026.100388_bib20","article-title":"Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)","author":"Sch\u00f6ttler","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.jtauto.2026.100388_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi therapeutic targeting C5 is efficacious in pre-clinical models of myasthenia gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jtauto.2026.100388_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jtauto.2026.100388_bib23","article-title":"A targeted complement inhibitor CRIg\/FH protects against experimental autoimmune myasthenia gravis in rats via immune modulation","volume":"13","author":"Song","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2026.100388_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103104","article-title":"Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders","volume":"21","author":"Mane-Damas","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2026.100388_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.expneurol.2015.03.010","article-title":"Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs","volume":"270","author":"Losen","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jtauto.2026.100388_bib26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jtauto.2026.100388_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-15187-2","article-title":"Refinement of the rat acetylcholine receptor-specific passive transfer myasthenia gravis model using subcutaneous injections: an update to the guidelines","volume":"15","author":"Arets","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jtauto.2026.100388_bib28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0022-3565(25)28988-1","article-title":"The route of absorption of intraperitoneally administered compounds","volume":"178","author":"Lukas","year":"1971","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.jtauto.2026.100388_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585108","article-title":"Soluble membrane attack complex: biochemistry and immunobiology","volume":"11","author":"Barnum","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2026.100388_bib30","first-page":"66","article-title":"Complement activation during surgical procedures","volume":"146","author":"Hahn-Pedersen","year":"1978","journal-title":"Surg. Gynecol. Obstet."},{"key":"10.1016\/j.jtauto.2026.100388_bib31","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/0090-1229(82)90329-4","article-title":"Effects of anesthesia and operation on the classical pathway of complement activation","volume":"23","author":"Lewis","year":"1982","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.jtauto.2026.100388_bib32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001107","article-title":"Anti-C2 antibody ARGX-117 inhibits complement in a disease model for multifocal motor neuropathy","volume":"9","author":"Budding","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jtauto.2026.100388_bib33","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.ajpath.2016.05.025","article-title":"Silencing of Dok-7 in adult rat muscle increases susceptibility to passive transfer myasthenia gravis","volume":"186","author":"Gomez","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jtauto.2026.100388_bib34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.nbd.2009.03.008","article-title":"Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding","volume":"35","author":"Martinez-Martinez","year":"2009","journal-title":"Neurobiol. Dis."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909026000419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909026000419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:47:34Z","timestamp":1793861254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909026000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":34,"alternative-id":["S2589909026000419"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2026.100388","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-C2\u2013mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2026.100388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100388"}}